ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Buonfrate D et al.2020. The global prevalence of Strongyloides stercoralis infection. Pathogens 9.
-
2.
Requena-Mendez A , Buonfrate D , Gomez-Junyent J , Zammarchi L , Bisoffi Z , Munoz J , 2017. Evidence-based guidelines for screening and management of strongyloidiasis in non-endemic countries. Am J Trop Med Hyg 97: 645–652.
-
3.
Boggild AK , Libman M , Greenaway C , McCarthy AE , Committee to Advise on Tropical Medicine, Travel , 2016. CATMAT statement on disseminated strongyloidiasis: prevention, assessment and management guidelines. Can Commun Dis Rep 42: 12–19.
-
4.
Montes M , Sawhney C , Barros N , 2010. Strongyloides stercoralis: there but not seen. Curr Opin Infect Dis 23: 500–504.
-
5.
Boulware DR et al.2007. Maltreatment of Strongyloides infection: case series and worldwide physicians-in-training survey. Am J Med 120: 545.e1–545.e8.
-
6.
Asundi A et al.2019. Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis. Lancet Glob Health 7: e236–e48.
-
7.
Statistics Canada , 2017. 2016 Census Topic: Immigration and Ethnocultural Diversity. Available at: https://www12.statcan.gc.ca/census-recensement/2016/rt-td/imm-eng.cfm. Accessed December 13, 2021.
-
8.
Group RC et al.2021. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 384: 693–704.
-
9.
Geri G et al.2015. Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature. Infection 43: 691–698.
-
10.
Abdulaziz K et al.2015. National survey of physicians to determine the effect of unconditional incentives on response rates of physician postal surveys. BMJ Open 5: e007166.
-
11.
Muhi S , Ko DK , McGuinness SL , Biggs BA , Mahanty S , Delany C , 2020. A mixed-method analysis of screening for Strongyloides stercoralis prior to immunosuppression: a problem of limited bandwidth? Intern Med J.
-
12.
Statistics Canada , 2019. Vancouver—A Data Story on Ethnocultural Diversity and Inclusion. Available at: https://www150.statcan.gc.ca/n1/pub/11-631-x/11-631-x2019004-eng.htm. Accessed December 24, 2021.
-
13.
RECOVERY Collaborative Group , et al.2020. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 384: 693–704.
-
14.
Lier AJ et al.2020. Case report: disseminated strongyloidiasis in a patient with COVID-19. Am J Trop Med Hyg 103: 1590–1592.
-
15.
Gautam D , Gupta A , Meher A , Siddiqui F , Singhai A , 2021. Corticosteroids in COVID-19 pandemic have the potential to unearth hidden burden of strongyloidiasis. IDCases 25: e01192.
-
16.
Marchese V et al.2021. Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. Infection 49: 539–542.
-
17.
Pereira CVM , Mastandrea GRA , Medeiros A , Gryschek RCB , Paula FM , Corral MA , 2021. COVID-19 and strongyloidiasis: what to expect from this coinfection? Clinics (São Paulo) 76: e3528.
-
18.
Barkati S , Greenaway C , Libman MD , 2021. Strongyloidiasis in immunocompromised migrants to non-endemic countries in the era of COVID-19: what is the role for presumptive ivermectin? J Travel Med.
-
19.
Stauffer WM , Alpern JD , Walker PF , 2020. COVID-19 and dexamethasone: a potential strategy to avoid steroid-related Strongyloides hyperinfection. JAMA 324: 623–624.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 406 | 406 | 12 |
| Full Text Views | 40 | 40 | 10 |
| PDF Downloads | 49 | 49 | 9 |
Evaluation of Strongyloides Awareness and Knowledge among Canadian Physicians Caring for Patients At Risk for Severe Strongyloidiasis: A National Cross-sectional Survey
ABSTRACT.
In Canada, a substantial proportion of migrants come from strongyloidiasis-endemic regions. Systematic screening for Strongyloides is not performed in immunocompromised patients in whom this infection could be potentially fatal. We aim to assess the level of Strongyloides awareness and knowledge among Canadian physicians caring for immunocompromised patients and identify factors currently associated with screening. Using an online survey distributed through Canadian medical associations, we collected information on physicians’ demographics, practice setting, overall awareness and knowledge of Strongyloides, and current practices. Descriptive analysis and logistic regression models were performed to identify the factors associated with Strongyloides screening. Nineteen national and provincial medical associations agreed to participate. Between November 2020 and August 2021, 368 of 5,194 (7%) physicians that were contacted responded to our survey. Quebec (46%) and Ontario (24%) were the most responsive. Sixty-nine percent of respondents practiced medicine in academic settings. Infectious disease (ID) specialists/medical microbiologists (38%) followed by nephrologists (33%) were the most represented. Most respondents (95%) had heard about Strongyloides. However, 36% of non-ID specialists considered themselves unfamiliar. Forty percent of respondents did not or rarely performed screening for strongyloidiasis in high-risk populations. Screening was associated with younger-aged physicians (odds ratio [OR] 2.35; 95% confidence interval [CI] 1.07–5.18), physicians who frequently served migrants (OR 3.33; 95% CI 1.44–7.66), or those who had training in global health and ID/medical microbiology (OR 3.71; 95% CI 1.21–11.34 and OR 46.42; 95% CI 15.89–135.59, respectively). Our survey suggests a general lack of knowledge of Strongyloides among Canadian physicians that is associated with low rates of screening in high-risk populations.
- Supplemental Materials (PDF 453 KB)
Author Notes
Financial support: This work was supported by the Department of Medicine, McGill University, Montreal, Quebec Canada. C. P. Y. holds a “Chercheur-boursier clinicien” career award from the Fonds de recherche du Québec – Santé (FRQS).
Disclosure: The authors declare no competing financial interests.
Authors’ addresses: Samuel De l’Étoile-Morel, Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montreal, Quebec, Canada, E-mail: samuel.deletoile-morel@mail.mcgill.ca. Faheel Naeem, J. D. MacLean Centre for Tropical Diseases at McGill University, Montreal, Quebec, Canada, and Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada, E-mail: faheel.naeem@maiul.mcgill.ca. Mohammad Alghounaim, The Montreal Children’s Hospital, Division of Infectious Diseases, Department of Pediatrics, McGill University Health Centre, Montreal, Quebec, Canada, E-mail: mohammad.alghounaim@gmail.com. Makeda Semret, Cedric P. Yansouni, Michael D. Libman, and Sapha Barkati, Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montreal, Quebec, Canada, J. D. MacLean Centre for Tropical Diseases at McGill University, Montreal, Quebec, Canada, and Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada, E-mails: makeda.semret@mcgill.ca, yansouni@mcgill.ca, michael.libman@mcgill.ca, and sapha.barkati2@mcgill.ca.